Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Takeda and Protagonist Therapeutics have shared positive top-line results from a phase 3 trial of rusfertide in the rare ...

Nasa Hataoka and Cassie Porter were atop the leaderboard with a one-shot lead Friday after the second round of the Blue Bay ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...

KFDA approves Takedas Prucalopride capsules for metastatic colorectal cancer Approval granted for Takedas Prucalopride ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Takeda made it rain zebras at a Boston Celtics game Friday. The stunt saw 100 toy zebras parachute from the arena’s rafters ...